Physician profile
Charles Busse
NPI 1477590594
$1,917.66
in general payments reported to CMS, 2019-2025
20 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2021: $411 · 2022: $153 · 2023: $230 · 2024: $450 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $438.06 | 2024-2025 | Voquezna |
| Inari Medical, INC. | $196.36 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Foundation Medicine, INC. | $165.02 | 2021 | |
| Abbott Laboratories | $143.33 | 2024-2025 | Freestyle Libre 3 |
| Ethicon INC. | $117.89 | 2021 | |
| Idorsia Pharmaceuticals US INC | $117.08 | 2022 | |
| Avanir Pharmaceuticals, INC. | $116.62 | 2019 | |
| Radius Health, INC. | $113.17 | 2019 | |
| Boston Scientific Corporation | $85.15 | 2021 | |
| Sanofi-Aventis U.S. LLC | $83.94 | 2019 | |
| Caris Mpi, INC. | $80.00 | 2025 | Mi Cancer Seek |
| Novo Nordisk INC | $54.49 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $46.77 | 2021-2024 | Farxiga |
| Glaxosmithkline, LLC. | $30.63 | 2021 | |
| Forte Bio-Pharma LLC | $30.54 | 2024 | Prolate, Nalocet |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.08 | 2024 | Caplyta |
| Merck Sharp & Dohme LLC | $22.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.50 | 2024 | |
| Abbvie INC. | $17.15 | 2023 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Busse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.